BioKinetic are currently recruiting male and female volunteers aged 18 to 80 years who suffer from painful osteoarthritis of the knee to take part in a research study.
Who is suitable for the study?
What will happen if I take part in this study?
Participation in this study involves up to 16 visits. There will be a period of up to 45 days for screening (where there could be a total of 5 visits), four administrations of MEDI7352 or placebo, and a 41-day follow-up period, for a total of up to 129 days per participant.
How much payment will I receive?
Up to £2,800 (This is to cover your time and any out of pocket expenses. You should note that any travel expenses incurred will be met by yourself and you will not be paid for attending the medical. The amount shown is for completion of the study). Payment will be forwarded to you at the end of the study, when all post-study medical results have been signed off by the study doctor
How long will I have to stay?
The study involves up to 16 visits. There will be a period of up to 45 days for screening (where there could be a total of 5 visits), and a 41-day follow-up period, for a total of up to 129 days per participant.
You must be available to stay on ALL dates for your group.
What is the drug being tested?
MEDI7352 is an investigational drug being developed to reduce your chronic pain as a potential treatment for osteoarthritis (OA) pain.
What else should I know?
To make sure that you are suitable for this study you will have to undergo a thorough medical, details of which will be discussed with you prior to attending the medical. As part of the study requirements you may be required to have an X-ray taken of your knee and an MRI scan of the knees and hips. If you pass the medical you may be invited to participate in the study If you would like to hear more details about the study, and to book a medical, please call our recruitment team on 028 90 81 83 85 and quote ref 14614.
Medicals to determine eligibility for this study will take place on the following dates:
Sign up for this trial